The Effect of Combined Therapy with a Proton Pump Inhibitor and Rebamipide on the Clinical Course and Morphofunctional Changes of the Esophageal Mucosa in Patients with Non-Erosive Reflux Disease

Aim: to evaluate the effect of combined therapy with a proton pump inhibitor and rebamipide on clinical manifestations and morphofunctional changes in the esophageal mucosa in patients with non-erosive reflux disease.

Materials and methods. The study included 39 patients with non-erosive reflux disease randomized into the main group (omeprazole 20 mg/day + rebamipide 300 mg/day) and the comparison group (omeprazole 20 mg/day). The duration of treatment was 4 weeks. Histological examination of esophageal mucosa biopsies (hematoxylin-eosin staining), morphometry of intercellular spaces, and immunohistochemical assessment of tight junction protein expression (claudin-1, -4, occludin) were performed. Symptoms were evaluated using the Likert scale.

Results. The combined therapy group showed significant reductions in heartburn severity (p < 0.001) and belching (p = 0.004), with absent/mild symptoms in 63.7 and 72.4 % of patients, respectively. In the proton pump inhibitor monotherapy group, 53 % of patients retained moderate or severe heartburn. Morphologically, the combined group demonstrated reduced eosinophilic infiltration (p = 0.030). Occludin expression increased in both groups but reached statistical significance only in the monotherapy group (p = 0.046).

Conclusion. The combined therapy with proton pump inhibitor and rebamipide improves symptoms and morphological outcomes in non-erosive reflux disease. Increased occludin expression suggests restored integrity of intercellular junctions. Further studies with larger cohorts and extended follow-up are needed to confirm these findings.

1. Ivashkin V.T., Trukhmanov A.S., Maev I.V., Drapkina O.M., Livzan M.A., Martynov A.I., et al. Diagnosis and treatment of gastroesophageal reflux disease (Clinical guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–35. (In Russ.). DOI: 10.22416/1382-4376-2024-34-5-111-135

2. Nirwan J.S., Hasan S.S., Babar Z.-U.-D., Conway B.R., Ghori M.U. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis. Sci Rep. 2020;10(1):5814. DOI: 10.1038/s41598-020-62795-1

3. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V., et al. Recommendations of the Russian Gastroenterological Association in diagnosis and treatment of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97

4. Zerbib F., Bredenoord A.J., Fass R., Kahrilas P.J., Roman S., Savarino E., et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075. DOI: 10.1111/nmo.14075

5. Makushina A.A., Trukhmanov A.S., Storonova O.A., Paraskevova A.V., Ivashkin V.T. Refractory non-erosive reflux disease: Characteristics of pathogenesis, diagnosis and treatment. Pediatric Nitrition. 2024;22(1):40–50. (In Russ.). DOI: 10.20953/17275784-2024-1-40-50

6. Kuznetsov S.L., Mushkambarov N.N. Histology, cytology and embryology. 3rd ed., corrected and supplemented. Moscow: “Meditsinskoe informatsionnoe agentstvo” Publ., 2016. (In Russ.).

7. Oshima T., Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol. 2016;51(8):768–78. DOI: 10.1007/s00535-016-1207-z

8. Gweon T.G., Park J.H., Kim B.W., Choi Y.K., Kim J.S., Park S.M., et al. Additive effects of rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease. Gut Liver. 2018;12(1):46–50. DOI: 10.5009/gnl17078

9. Ustaoglu A., Nguyen A., Spechler S., Sifrim D., Souza R., Woodland P. Mucosal pathogenesis in gastro-esophageal reflux disease. Neurogastroenterol Motil. 2020;32(12):e14022. DOI: 10.1111/nmo.14022

10. Björkman E.V.C., Edebo A., Oltean M., Casselbrant A. Esophageal barrier function and tight junction expression in healthy subjects and patients with gastroesophageal reflux disease: Functionality of esophageal mucosa exposed to bile salt and trypsin in vitro. Scand J Gastroenterol. 2013;48(10):1118–26. DOI: 10.3109/00365521.2013.828772

11. Farré R., Fornari F., Blondeau K., Vieth M., De Vos R., Bisschops R., et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut. 2010;59(2):164–9. DOI: 10.1136/gut.2009.194191

12. van Malenstein H., Farré R., Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol. 2008;103(4):1021–8. DOI: 10.1111/j.1572-0241.2007.01688.x

13. Caviglia R., Ribolsi M., Gentile M., Rabitti C., Emerenziani S., Guarino M.P.L., et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25(5):629–36. DOI: 10.1111/j.1365-2036.2006.03237.x

14. Chen X., Oshima T., Shan J., Fukui H., Watari J., Miwa H. Bile salts disrupt human esophageal squamous epithelial barrier function by modulating tight junction proteins. Am J Physiol Gastrointest Liver Physiol. 2012;303(2):199–208. DOI: 10.1152/ajpgi.00454.2011

15. Demura T.A. Barrett’s esophagus as a precancerous condition, features of tumor marker expression: Cand. Sci. (Med.) Dissertation. Moscow, 2008. (In Russ.).

16. Cheng E., Zhang X., Huo X., Yu C., Zhang Q., Wang D.H., et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62(6):824–32. DOI: 10.1136/gutjnl-2012-302250

17. Ivashkin V.T., Lapina T.L., Maev I.V., Drapkina O.M., Kozlov R.S., Sheptulin A.A., et al. Clinical practice guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori diagnostics and treatment in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72–93. (In Russ.). DOI: 10.22416/1382-4376-2022-32-6-72-93

18. Sakurai K., Sasabe H., Koga T., Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: Identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38(5):487–94. DOI: 10.1080/1071576042000209808

19. Naito Y., Yoshikawa T., Tanigawa T., Sakurai K., Yamasaki K., Uchida M., et al. Hydroxyl radical scavenging by rebamipide and related compounds: Electron paramagnetic resonance study. Free Radic Biol Med. 1995;18(1):117–23. DOI: 10.1016/0891-5849(94)00110-6

20. Naito Y., Yoshikawa T. Rebamipide: A gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261–70. DOI: 10.1586/egh.10.25

21. Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E., et al. 15th anniversary of rebamipide: Looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl 1):S3–11. DOI: 10.1007/s10620-005-2800-9

22. Yoon S.M., Ji J.W., Kim D.H., Kim H.W., Kim K.B., Choi S., et al. 11 — The effect of rebamipide in patients with gastroesophageal reflux disease, including non-erosive reflux disease: A multi-center, randomized, single-blind, placebo-controlled study. Gastroenterology. 2019;156(6 Suppl 1):S-5. DOI: 10.1016/s0016-5085(19)36783-6

23. Yerian L., Fiocca R., Mastracci L., Riddell R., Vieth M., Sharma P., et al. Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: The Esohisto project. Dig Dis Sci. 2011;56(9):2656–65. DOI: 10.1007/s10620-011-1624-z

24. Fiocca R., Mastracci L., Riddell R., Takubo K., Vieth M., Yerian L., et al. Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: The Esohisto project. Hum Pathol. 2010;41(2):223–31. DOI: 10.1016/j.humpath.2009.07.016

25. Hong S.J., Park S.H., Moon J.S., Shin W.G., Kim J.G., Lee Y.C., et al. The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis: An international multicenter study. Gut Liver. 2016;10(6):910–6. DOI: 10.5009/gnl15537

26. Yoshida N., Kamada K., Tomatsuri N., Suzuki T., Takagi T., Ichikawa H., et al. Management of recurrence of symptoms of gastroesophageal reflux disease: Synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393–8. DOI: 10.1007/s10620-010-1166-9

27. Kim J.J., Kim N., Park J.H., Kim Y.S., Lee S.M., Lee D.H., et al. Comparison of tight junction protein-related gene mRNA expression levels between male and female gastroesophageal reflux disease patients. Gut Liver. 2018;12(4):411–9. DOI: 10.5009/gnl17419

28. Asaoka D., Miwa H., Hirai S., Ohkawa A., Kurosawa A., Kawabe M., et al. Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis. J Gastroenterol. 2005;40(8):781–90. DOI: 10.1007/s00535-005-1628-6

29. Oguro M., Koike M., Ueno T., Asaoka D., Mori H., Nagahara A., et al. Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease. J Gastroenterol. 2011;46(5):629–38. DOI: 10.1007/s00535-011-0390-1